Revelstoke Capital Partners ("Revelstoke") sponsored the transaction in which it, Yukon and other institutional co-investors acquired a majority equity interest in Schryver. Subordinated debt financing was led by Yukon. The senior credit facility was Agented and underwritten by Ally Corporate Finance. Management will continue to own a meaningful interest in the Company.
Revelstoke will provide Schryver strategic guidance and additional capital to accelerate its organic growth, pursue selective acquisitions, and continue to leverage its scalable business model for continued growth.
"We are pleased to partner with the Revelstoke team, who share our commitment to outstanding customer service," said Mark Schryver, Founder of Schryver. "With their support, we have the ability to make investments that will further strengthen our capabilities and the value-added services we bring to our customers."
"We are excited to partner with the Schryver Medical team to support the Company’s continued growth in the mobile imaging and laboratory diagnostics market," noted Mark King, Managing Partner and CEO of Revelstoke. "We believe that the Schryver platform represents a compelling opportunity to invest in a differentiated service provider to the long term post-acute setting and are confident in the management team’s ability to further solidify its position as a leader in the industry. Schryver is well-positioned to accelerate its organic growth as well as pursue acquisitions that will further expand its service offerings and geographic coverage."
"We are once again excited to be partnering with the Revelstoke team. Their hands-on approach and experience within the healthcare industry are attributes we greatly value," said Michael Hall, Managing Partner of Yukon. "We are confident that with Revelstoke’s leadership alongside the strong reputation, operational expertise, and industry experience of the Company’s senior management team, Schryver will continue its impressive track record of growth."
